Literature DB >> 26903515

Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.

Luuk C T Dohmen1, Adriana Navas2, Deninson Alejandro Vargas2, David J Gregory3, Anke Kip4, Thomas P C Dorlo5, Maria Adelaida Gomez6.   

Abstract

Within its mammalian host, Leishmania resides and replicates as an intracellular parasite. The direct activity of antileishmanials must therefore depend on intracellular drug transport, metabolism, and accumulation within the host cell. In this study, we explored the role of human macrophage transporters in the intracellular accumulation and antileishmanial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cutaneous leishmaniasis (CL). Membrane transporter gene expression in primary human macrophages infected in vitro with Leishmania Viannia panamensis and exposed to MLF showed modulation of ABC and solute liquid carrier transporters gene transcripts. Among these, ABCA3, a lipid transporter, was significantly induced after exposure to MLF, and this induction was confirmed in primary macrophages from CL patients. Functional validation of MLF as a substrate for ABCA3 was performed by shRNA gene knockdown (KD) in THP-1 monocytes. Intracellular accumulation of radiolabeled MLF was significantly higher in ABCA3(KD) macrophages. ABCA3(KD) resulted in increased cytotoxicity induced by MLF exposure. ABCA3 gene expression inversely correlated with intracellular MLF content in primary macrophages from CL patients. ABCA3(KD) reduced parasite survival during macrophage infection with an L. V. panamensis strain exhibiting low in vitro susceptibility to MLF. Confocal microscopy showed ABCA3 to be located in the cell membrane of resting macrophages and in intracellular compartments in L. V. panamensis-infected cells. These results provide evidence of ABCA3 as an MLF efflux transporter in human macrophages and support its role in the direct antileishmanial effect of this alkylphosphocholine drug.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  ABC transporter; ABCA3; Leishmania; drug transport; host-pathogen interaction; macrophage; miltefosine; pharmacodynamics

Mesh:

Substances:

Year:  2016        PMID: 26903515      PMCID: PMC4850301          DOI: 10.1074/jbc.M115.688168

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine.

Authors:  Vanessa Yardley; Simon L Croft; Simonne De Doncker; Jean-Claude Dujardin; Siddhartha Koirala; Suman Rijal; Cesar Miranda; Alejandro Llanos-Cuentas; Francois Chappuis
Journal:  Am J Trop Med Hyg       Date:  2005-08       Impact factor: 2.345

2.  Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

Authors:  Patricia Escobar; Sangeeta Matu; Cláudia Marques; Simon L Croft
Journal:  Acta Trop       Date:  2002-02       Impact factor: 3.112

3.  Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome.

Authors:  Naeun Cheong; Muniswamy Madesh; Linda W Gonzales; Ming Zhao; Kevin Yu; Philip L Ballard; Henry Shuman
Journal:  J Biol Chem       Date:  2006-01-16       Impact factor: 5.157

4.  Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator.

Authors:  J M Pérez-Victoria; F J Pérez-Victoria; A Parodi-Talice; I A Jiménez; A G Ravelo; S Castanys; F Gamarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  ABCA3 as a lipid transporter in pulmonary surfactant biogenesis.

Authors:  Nobuhiro Ban; Yoshihiro Matsumura; Hiromichi Sakai; Yasukazu Takanezawa; Mayumi Sasaki; Hiroyuki Arai; Nobuya Inagaki
Journal:  J Biol Chem       Date:  2007-01-30       Impact factor: 5.157

6.  Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models.

Authors:  G Roy; C Dumas; D Sereno; Y Wu; A K Singh; M J Tremblay; M Ouellette; M Olivier; B Papadopoulou
Journal:  Mol Biochem Parasitol       Date:  2000-10       Impact factor: 1.759

7.  Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  A E Kip; H Rosing; M J X Hillebrand; M M Castro; M A Gomez; J H M Schellens; J H Beijnen; T P C Dorlo
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-06-24       Impact factor: 3.205

Review 8.  Multidrug resistance phenotype mediated by the P-glycoprotein-like transporter in Leishmania: a search for reversal agents.

Authors:  J M Pérez-Victoria; A Di Pietro; D Barron; A G Ravelo; S Castanys; F Gamarro
Journal:  Curr Drug Targets       Date:  2002-08       Impact factor: 3.465

9.  Miltefosine for new world cutaneous leishmaniasis.

Authors:  J Soto; B A Arana; J Toledo; N Rizzo; J C Vega; A Diaz; M Luz; P Gutierrez; M Arboleda; J D Berman; K Junge; J Engel; H Sindermann
Journal:  Clin Infect Dis       Date:  2004-04-09       Impact factor: 9.079

10.  The C. elegans cell corpse engulfment gene ced-7 encodes a protein similar to ABC transporters.

Authors:  Y C Wu; H R Horvitz
Journal:  Cell       Date:  1998-06-12       Impact factor: 41.582

View more
  5 in total

1.  Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.

Authors:  Maria Claudia Barrera; Laura Jimena Rojas; Austin Weiss; Olga Fernandez; Diane McMahon-Pratt; Nancy G Saravia; Maria Adelaida Gomez
Journal:  Acta Trop       Date:  2017-08-24       Impact factor: 3.112

2.  Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study.

Authors:  Anke E Kip; Séverine Blesson; Fabiana Alves; Monique Wasunna; Robert Kimutai; Peninah Menza; Bewketu Mengesha; Jos H Beijnen; Asrat Hailu; Ermias Diro; Thomas P C Dorlo
Journal:  J Antimicrob Chemother       Date:  2021-04-13       Impact factor: 5.790

3.  Strategies to gain novel Alzheimer's disease diagnostics and therapeutics using modulators of ABCA transporters.

Authors:  Jens Pahnke; Pablo Bascuñana; Mirjam Brackhan; Katja Stefan; Vigneshwaran Namasivayam; Radosveta Koldamova; Jingyun Wu; Luisa Möhle; Sven Marcel Stefan
Journal:  Free Neuropathol       Date:  2021-12-13

4.  Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.

Authors:  Markela Koniordou; Stephen Patterson; Susan Wyllie; Karin Seifert
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

5.  Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.

Authors:  Andrew A Voak; Joseph F Standing; Nuno Sepúlveda; Andy Harris; Simon L Croft; Karin Seifert
Journal:  J Antimicrob Chemother       Date:  2018-05-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.